Pennsylvania Mennonite community creates its own biotech firm after successful gene therapy in a calf with maple syrup urine disease

A tight‑knit Mennonite community in Lancaster County, Pennsylvania, has long faced a high rate of maple syrup urine disease (MSUD), a rare genetic disorder that can be fatal. With few external biotech options, local families and clinicians felt compelled to find a solution themselves.

Researchers at a small medical clinic used a viral vector to deliver a functional MSUD gene to a newborn calf named Petunia, who suffered from the bovine form of the disease. After two sleepless nights, the calf survived and has grown into a healthy five‑year‑old heifer, demonstrating that the gene therapy can correct the metabolic defect.

Buoyed by the animal success, the team aims to translate the approach to human patients and has launched a community‑driven drug company to develop and eventually commercialize the therapy. The effort seeks to give families in the region a one‑time treatment option for a condition that has long lacked effective remedies.